



CGM Benefits Extend Beyond Intensive Insulin Therapy

CONNECT [Trial link](#)

Adults with type 2 diabetes NOT using insulin:

A1C Reduction

- CGM: -1.6%
- BGM: -0.7%

Time in Range (TIR)

- CGM users gains +21% TIR (~5 hours/day in range)

Reached A1C <7.0%

- CGM: 46%
- BGM: 24%

FreeDM2 [Trial link](#)

Adults with type 2 diabetes using basal insulin.

A1C Reduction

- CGM: -1.0%
- BGM: -0.5%

Time in Range (TIR)

- CGM users gains +10% TIR (~2.5 hours/day in range)

Participants with baseline A1C >9.0% had greatest A1C reduction (-1.1%).

Key Takeaway: CGM improves glycemic outcomes in adults with type 2 diabetes both on and off insulin.



**SOUTHEASTERN OHIO
REGIONAL QI HUB**



**OHIO COLLEGES OF MEDICINE
GOVERNMENT
RESOURCE CENTER**



THE DIABETES INSTITUTE
Heritage College of Osteopathic Medicine



New Medications Reshaping Type 2 Diabetes Care

Transcend-T2D-1 [Trial link](#)

Triple GIP+GLP-1+Glucagon Receptor Agonist

A1C Reduction

- Up to -2.0%

Weight Loss

- Up to -15%

Reached A1C <6.5%

- Achieved by 85% of participants

REIMAGINE-3 [Trial link](#)

Cagrilinitide + Semaglutide

A1C Reduction

- Up to -2.3%

Weight Loss

- -10-12%

Reached A1C <6.5%

- Achieved by 60% of participants

ACHIEVE-5 [Trial link](#)

Orforglipron (oral small molecule GIP-1)

A1C Reduction

- Up to -1.8%

Weight Loss

- -2.6-5.4%

Reached A1C <6.5%

- Up to 60% of participants

